In simple terms
When treating fast-growing cancers, doctors often start with a strong, powerful phase of treatment called induction therapy. Think of it like putting out the main blaze of a fire before dealing with the remaining embers. The goal is to hit the cancer hard right from the beginning to shrink tumours or clear cancer cells from your blood and bone marrow. Once induction therapy successfully pushes the disease into remission, your team follows up with further, often milder treatments to keep it from coming back.
Key takeaways
- The initial, highly intensive phase of a multi-step cancer treatment plan.
- Primary goal is to induce complete remission or substantial tumour shrinkage.
- Standard of care for acute leukaemias, multiple myeloma, and select solid tumours.
- Followed by consolidation, maintenance, or definitive surgery.
Definition
Induction therapy represents the opening and typically most aggressive phase of a phased oncological strategy. In haematological malignancies like acute leukaemias, induction regimens deliver high-dose combination chemotherapy designed to clear abnormal blast cells from the bone marrow and peripheral circulation, allowing normal haematopoietic cells to recover and resume blood cell production.
In the context of solid tumours, induction therapy is often synonymous with neoadjuvant therapy, delivered upfront before planned local therapies like major surgery or definitive radiotherapy. By rapidly shrinking primary tumours and eradicating micrometastatic disease, induction therapy aims to downstage the disease, improve surgical resectability, and gauge how responsive the tumour is to specific pharmaceutical agents.
Why it matters
Achieving an optimal response during induction therapy is one of the strongest indicators of long-term survival. In leukaemias, entering remission after the first induction cycle significantly improves the likelihood of cure. For solid tumours, shrinking the mass can transform an inoperable tumour into an operable one and preserve vital organs. Because induction is intensive, it requires close medical monitoring, clear patient education regarding side effects, and proactive management of potential complications.
Related biomarkers and tests
Effectiveness is evaluated through follow-up bone marrow biopsies, minimal residual disease (MRD) flow cytometry, molecular PCR assays, or repeat cross-sectional imaging such as CT or PET-CT scans to verify tumour shrinkage and confirm that remission criteria have been met.
Related cancers
Induction therapy is fundamental in managing acute myeloid leukaemia (AML), acute lymphoblastic leukaemia (ALL), and multiple myeloma. It is also routinely used for locally advanced head and neck cancers, non-small cell lung cancer, oesophageal carcinoma, and high-risk neuroblastoma.
Related treatments
Following induction, treatment transitions into subsequent phases. In leukaemias, successful induction is followed by consolidation or stem cell transplantation, then maintenance therapy. In solid tumours, a good response enables definitive surgery or radiotherapy to eliminate residual disease.
Frequently asked questions
What happens if induction therapy does not cause remission?
If induction therapy fails to achieve remission, the disease is considered refractory. The oncology team will re-evaluate the tumour with fresh testing to identify resistance mechanisms and recommend second-line induction regimens, targeted therapies, or clinical trials.
How does induction therapy differ from consolidation therapy?
Induction therapy is the opening phase designed to rapidly destroy the bulk of cancer cells and induce remission. Consolidation therapy is given immediately after remission is achieved to eradicate any remaining undetectable cancer cells and prevent disease recurrence.
Is induction therapy given in the hospital?
For acute leukaemias, induction therapy almost always requires an inpatient hospital stay of three to four weeks due to temporary bone marrow suppression and infection risks. For solid tumours, induction chemotherapy is often administered in an outpatient infusion clinic.
References
- 1.NCI Dictionary of Cancer Terms: Induction Therapy— National Cancer Institute
- 2.Treating Acute Myeloid Leukemia (AML)— American Society of Clinical Oncology (Cancer.Net)
- 3.ESMO Clinical Practice Guidelines: Acute Leukaemia— European Society for Medical Oncology
Ask GetOnco AI
Get personalised answers about Induction Therapy — The First Phase of Intensive Treatment from your AI cancer care coordinator.
- Can you explain Induction Therapy — The First Phase of Intensive Treatment in simple words?
- What does Induction Therapy — The First Phase of Intensive Treatment mean for my treatment plan?
- What questions should I ask my oncologist about Induction Therapy — The First Phase of Intensive Treatment?
- What next steps do you recommend regarding Induction Therapy — The First Phase of Intensive Treatment?
GetOnco AI provides educational information and never replaces advice from your medical team.
Explore related topics
More in this section
Last reviewed August 1, 2026
Medical disclaimer
Educational information only. GetOnco is software, not a medical provider, and does not diagnose disease or recommend treatments. Always discuss your situation with qualified healthcare professionals.